BQ-123
Phase 1Small molecule
BQ-123 is one of 55 small molecule programs targeting Chronic Kidney Disease. It is currently in Phase 1.
2
Indications
10
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
172 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Auryxia
KKeryx Biopharmaceuticals
Phase 3
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Myocardial Infarction1 trial
Microvascular Dysfunction1 trial
Pulmonary Hypertension1 trial
The Role of Endothelin in Pulmonary Hypertension
Completed·—·Phase 2·NCT00759408·38 enrolled
5 more indications
Vasoconstriction1 trial
Chronic Kidney Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BQ-123. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMedical University of Vienna